Ardelyx touts a PhIII hyperphosphatemia success for tenapanor, looking to calm fears over diarrhea
Ardelyx has been on a years-long roller coaster ride with their drug tenapanor. But early this morning the biotech $ARDX pulled the wraps off a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
